EMA accepts GSK’s bepirovirsen filing in chronic hepatitis B

GSK said the European Medicines Agency has accepted its marketing authorisation application for bepirovirsen, an investigational antisense oligonucleotide for adults with chronic hepatitis B. The March 27, 2026 filing acceptance means the EMA has started its review of a candidate GSK is positioning as a potential first-in-class finite treatment, based on phase III B-Well 1 and B-Well 2 data showing statistically significant, clinically meaningful functional cure rates versus standard of care alone. GSK has said bepirovirsen is not approved anywhere in the world, and that the same phase III package has also supported a U.S. filing, which the FDA accepted for priority review on April 28, 2026. (sec.gov)

Why it matters: For veterinary professionals, this is a human-health regulatory story, but it’s still relevant because chronic viral disease management increasingly centers on finite regimens and “functional cure” rather than indefinite suppression alone. Bepirovirsen targets hepatitis B viral RNA and is being developed to reduce hepatitis B surface antigen and potentially restore immune control, a strategy that reflects broader interest in nucleic acid therapeutics and combination approaches across medicine. The EMA acceptance also lands as regulators update how they evaluate chronic hepatitis B products aimed at functional cure, underscoring how quickly standards are shifting for antiviral development. (sec.gov)

What to watch: Watch for detailed B-Well phase III data at a scientific congress in 2026, peer-reviewed publication, and the EMA’s review timeline alongside the FDA’s October 26, 2026 PDUFA date. (sec.gov)